Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Revenue (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Revenue for 10 consecutive years, with $9.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 11.64% year-over-year to $9.4 million, compared with a TTM value of $37.3 million through Sep 2025, up 13.24%, and an annual FY2024 reading of $34.9 million, up 44.75% over the prior year.
  • Revenue was $9.4 million for Q3 2025 at Sunshine Biopharma, roughly flat from $9.4 million in the prior quarter.
  • Across five years, Revenue topped out at $9.6 million in Q4 2024 and bottomed at $40058.0 in Q1 2021.
  • Average Revenue over 5 years is $4.8 million, with a median of $5.6 million recorded in 2023.
  • The sharpest move saw Revenue surged 4528.68% in 2022, then grew 1.15% in 2025.
  • Year by year, Revenue stood at $85118.0 in 2021, then soared by 4528.68% to $3.9 million in 2022, then surged by 94.94% to $7.7 million in 2023, then increased by 24.93% to $9.6 million in 2024, then dropped by 1.85% to $9.4 million in 2025.
  • Business Quant data shows Revenue for SBFM at $9.4 million in Q3 2025, $9.4 million in Q2 2025, and $8.9 million in Q1 2025.